ArticleProstate cancer and prostatic diseases2026
Treatment cycles per unit prostate volume (CPV) for transurethral water vapor therapy (Rezūm) in catheter-dependent patients.
Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Perirectal spacers and endorectal balloons in external beam radiotherapy for prostate cancer: a review of prospective studies.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- The double-decker technique for transurethral water vapor therapy (Rezūm) in catheter-dependent patients: A step-by-step guide and results from a prospective registry.Investigative and clinical urology · 2026Article
- Comparison of prostatic urethral lift (PUL) versus water vapour thermal therapy (WVTT): A focus on drug-free status and unplanned admissions.BJUI compass · 2026Article
- Asia-Pacific collaborative consensus statements on water vapor thermal therapy (Rezūm) incorporating a systematic review, a two-round Delphi survey, and a consensus meeting.Prostate international · 2026Article
- The "swipe" technique for prostatic urethral lift: a comparative analysis of 200 patients in a prospective cohort.Prostate international · 2026Article
- Thulium fiber laser enucleation of the prostate with SOLTIVE™ SuperPulsed laser systems: a prospective evaluation of early outcomes in an Asian cohort.Frontiers in urology · 2026Article
- Transurethral water vapor therapy (Rezūm) for acute urinary retention with obstructive uropathy: a prospective cohort study with one-year follow-up.Prostate international · 2025Article
- "Re: does biodegradable peri-rectal spacer mitigate treatment toxicities in radiation therapy for localized prostate cancer-a systematic review and meta-analysis."Prostate cancer and prostatic diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor transurethral water vapor therapy (Rezūm), the number of water vapor treatment cycles has classically been determined by the prostate length, or the fields of vision (FOV). Apart from treating lower urinary tract symptoms, there is emerging evidence on Rezūm for refractory retention. We aim to investigate the optimal number of treatment cycles for Rezūm in catheter-dependent refractory retention.
methodsFrom 02/2021 to 09/2023, 168 consecutive catheter-dependent patients undergoing Rezūm at three centres were included in this prospective registry. Treatment Cycles Per Unit Prostate Volume (CPV) was calculated by dividing the number of treatment cycles by the prostate size. After propensity score matching of age and prostate size, 144 patients were analyzed in the CPV ≤ 0.15 and CPV > 0.15 groups in 1:1 ratio. The primary outcome was the International Prostate Symptom Score (IPSS) at 1-year follow-up. Secondary outcomes included catheter removal time, 30-day readmission rates, prostate-specific antigen (PSA) reduction. Logistic regression model and linear mixed model were used.
resultsThe CPV > 0.15 group demonstrated significantly better IPSS at 1-year follow-up (adjusted mean difference -2.8 points, p = 0.040), and lower 30-day readmission rates (4.2% vs 16.7%, OR 0.22, p = 0.029). Greater PSA reduction was observed in the higher CPV group at 3 months (adjusted mean difference of log-transformed PSA: -0.4 ng/ml, p = 0.022). Median catheter removal times were 14 days (interquartile range 9-29 days) and 15 days (interquartile range 12-40 days) for lower and higher CPV groups respectively (p = 0.059). Six-week IPSS and IPSS-QoL (quality of life score) were similar (p = 0.359 and p = 0.464 respectively).
conclusionHigher CPV (>0.15) in Rezūm demonstrated superior 1-year IPSS, lower 30-day readmission rates in our matched cohort. A more aggressive treatment approach, contrasting to the standard FOV-based approach, may benefit catheter-dependent patients.
Indexed as
Identifiers
40379864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.